CJC-1295
GHRH analog discussed for GH axis support.
You will almost never hear ipamorelin mentioned without CJC-1295, and there is a real reason researchers pair them.
Your COA Says 99.9%. That Number Can Be True and the Vial Still Be Short.
Purity tells you the composition of what's in the vial. It says nothing about how much is in there, and almost every certificate published to buyers answers the first question and quietly skips the second.
Tesamorelin Is Approved. CJC-1295 Is Living Off Its Reputation.
The GH-axis peptides are not one evidence base, they're a steep ladder, and the rung most buyers think they're standing on isn't the one they're on.
How it is thought to work
GHRH receptor signaling; GH axis modulation.
CJC-1295 No DAC is a short-acting copy of the body's own growth-hormone-releasing signal that tells the pituitary gland to release a brief burst of growth hormone, then clears the body in about 30 minutes.
Reported side effects
The most commonly reported side effects are mild flushing, headache, injection-site redness, mild water retention, and occasional hand tingling, most of which pass within 30-60 minutes of a dose.
Who should avoid it
People with active or recent cancer, serious heart conditions, pregnancy, uncontrolled diabetes, or known allergies to peptide products or benzyl alcohol are typically excluded from research protocols, and anyone considering this compound should consult a licensed clinician first.
What gets monitored
IGF-1 at baseline and again at 4-6 weeks; fasting glucose and HbA1c due to potential blood sugar elevation. [Source: Peptide Dosing Protocols]
What sources report
These are figures published elsewhere, reproduced with their source. Peppersite does not recommend an amount for CJC-1295 or for anything else, and nothing below has been checked against the study it came from.
| Amount | Frequency | Route | Reported by |
|---|---|---|---|
| 100 mcg per injection (1-2 mcg/kg saturation dose) | 2-3 times daily8-12 weeks | subcutaneous | Peptide Protocol WikiWhat it saysHide(secondary reference; provider confirmation required). |
| Standard: 200 mcg, once daily · Low: 100 mcg, once daily · High: 300 mcg, up to 3x daily | 1-3 times daily8-12 weeks · 4-6 weeks off | Subcutaneous (SubQ) | Peptide Dosing ProtocolsWhat it saysHide(secondary reference; provider confirmation required). Half-life: About 30 minutes. The standard dose is 200 mcg, administered once daily. |
| Non-DAC version referenced at 100-300 mcg (0.1-0.3 mg) per dose due to short half-life. Empty stomach preferred; avoid co-administration with carbohydrates or fats (insulin interference with GH release). | 1-3x daily · Morning, pre-workout, or before bedOn-cycle 8-12 weeks, off-cycle 6-12 weeks | subcutaneous | Peptide Therapy Reference Text, internal KB v4What it saysHide(Aug 2026), secondary reference; provider confirmation required. |
- 2-3 times daily8-12 weeks
- subcutaneous
- Peptide Protocol Wiki
What it saysHide
(secondary reference; provider confirmation required).
- 1-3 times daily8-12 weeks · 4-6 weeks off
- Subcutaneous (SubQ)
- Peptide Dosing Protocols
What it saysHide
(secondary reference; provider confirmation required). Half-life: About 30 minutes. The standard dose is 200 mcg, administered once daily.
- 1-3x daily · Morning, pre-workout, or before bedOn-cycle 8-12 weeks, off-cycle 6-12 weeks
- subcutaneous
- Peptide Therapy Reference Text, internal KB v4
What it saysHide
(Aug 2026), secondary reference; provider confirmation required.
- Bacteriostatic water
- 10 mg vial with 3 mL bacteriostatic water
Common questions
What is CJC-1295 No DAC?
CJC-1295 No DAC is a short-acting GHRH analog that tells the pituitary gland to release a single growth hormone pulse.
What is the common starting dose for CJC-1295 No DAC?
A common starting dose is 100 mcg once daily pre-bed in a fasted window.
What is CJC-1295 No DAC's half-life?
About 30 minutes.
How do you reconstitute a 10 mg CJC-1295 No DAC vial?
Use a 10 mg vial with 3 mL bacteriostatic water.
Check 10 mg in 3 mL in the calculator →How is CJC-1295 No DAC different from CJC-1295 with DAC?
The No DAC version is short-acting and usually dosed daily, while the DAC version lasts 6–8 days.
Why is CJC-1295 No DAC paired with Ipamorelin?
Both compounds push different pathways to create a larger GH pulse.
What are the most common side effects?
Common effects include flushing, headache, injection-site redness, and mild water retention.
Is CJC-1295 No DAC FDA-approved?
No, it is not FDA-approved for any use.
Sources
- 01Teichman et al. 2006 (JCEM, Phase 1)
- 02Ionescu and Frohman 2006 (JCEM)
- 03Alba et al. 2006 (preclinical)
- 04Jette et al. 2005 (Endocrinology)
- 05ConjuChem Phase 2, 2006 (NCT00267527, DAC version)
The reference sections above are imported from our compound knowledge base, which classes the evidence for CJC-1295 as emerging. That classification is the knowledge base’s, not ours, our own grade appears only where an audit is linked above. Research use only; nothing here is medical advice or a protocol.
Sermorelin is a synthetic 29-amino-acid analog of growth-hormone-releasing hormone (GHRH) studied in growth-hormone axis research.
Blend of Tesamorelin (GHRH analog) and Ipamorelin (GHRP), studied for GH-axis support, visceral fat, and recovery.
Glutathione is a tripeptide antioxidant central to cellular redox biology research.
Blend of retatrutide (triple incretin agonist) and MOTS-c (mitochondrial-derived peptide), studied for metabolic and body-composition research.
Semaglutide is one of the most widely studied weight-loss and diabetes drugs in the world.
5-Amino-1MQ is a small molecule studied for its potential to help the body shrink fat cells and raise NAD+ levels without cutting appetite.